Primary Surgery or Interval Debulking for Advanced Epithelial Ovarian Cancer: Does It Matter?

被引:26
|
作者
Markauskas, Algirdas [1 ]
Mogensen, Ole [1 ]
Christensen, Rene dePont [2 ]
Jensen, Pernille Tine [1 ]
机构
[1] Odense Univ Hosp, Dept Obstet & Gynaecol, DK-5000 Odense C, Denmark
[2] Univ Southern Denmark, Res Unit Gen Practice, Odense, Denmark
关键词
Debulking surgery; Epithelial ovarian cancer; Surgical complexity; Postoperative morbidity; Survival; NEOADJUVANT CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; QUALITY; RISK;
D O I
10.1097/IGC.0000000000000241
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of the present study was to investigate the surgical complexity, the postoperative morbidity, and the survival of the women after primary debulking surgery (PDS) and neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) for advanced epithelial ovarian cancer. Materials and Methods: We consecutively included all patients who underwent debulking surgery at our institution between January 2007 and December 2012 for stages IIIc and IV of epithelial ovarian cancer. Results: Of the 332 patients included, 165 (49.7%) underwent PDS, and 167 (50.3%) had NACT-IDS. Complete intraperitoneal cytoreduction was achieved in 70.9% after PDS and in 59.9 % after NACT-IDS. Residual disease of greater than 1 cm was left in 18.5% and 27.5% after PDS and NACT-IDS, respectively. Compared with NACT-IDS, PDS was associated with higher surgical complexity (P < 0.001), longer operating time (P < 0.001), greater blood loss (P < 0.001), longer hospitalization (P = 0.001), and a higher rate of major postoperative complications (26.7% vs 16.8%). No statistical difference in the median overall survival (OS) was found between the patients having complete cytoreduction and residual disease of 1 cm or less after NACT-IDS. Furthermore, no statistical difference in the median OS was found between the patients with macroscopic residual disease (<= 1 vs >1 cm) after NACT-IDS. Patients with residual disease of greater than 1 cm after PDS had a median OS of 15 months. Conclusions: We suggest that NACT-IDS may be a better treatment alternative for the group of highly selected women not suitable for PDS, where expected suboptimal cytoreduction does not have any appreciable survival benefit and exposes them for unnecessary risks. A substantial number of women who receive either PDS or NACT-IDS have greater than 1 cm of tumor tissue left after the operation. These women probably have no survival benefit from the operation, and future studies should focus on how to select these women preoperatively.
引用
收藏
页码:1420 / 1428
页数:9
相关论文
共 50 条
  • [41] Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer
    Lee, Jessica
    Curtin, John P.
    Muggia, Franco M.
    Pothuri, Bhavana
    Boyd, Leslie R.
    Blank, Stephanie V.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (01) : 55 - 63
  • [42] Radical Surgical Procedures in Advanced Ovarian Cancer and Differences Between Primary and Interval Debulking Surgery
    Mitsopoulos, Vasilis
    Innamaa, Anni
    Lippiatt, Jonathan
    Plevris, Nikolaos
    Biliatis, Ioannis
    ANTICANCER RESEARCH, 2020, 40 (10) : 5869 - 5875
  • [43] Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer
    Jessica Lee
    John P. Curtin
    Franco M. Muggia
    Bhavana Pothuri
    Leslie R. Boyd
    Stephanie V. Blank
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 55 - 63
  • [44] Primary versus Interval Debulking Surgery in Advanced Ovarian Cancer: Results from a Prospective Analysis
    Sehouli, J.
    Savvatis, K.
    Braicu, E-I
    Schmidt, S. -C.
    Lichtenegger, W.
    Fotopoulou, C.
    ONKOLOGIE, 2010, 33 : 112 - 112
  • [45] Compliance to treatment guidelines and survival in women undergoing interval debulking surgery for advanced epithelial ovarian cancer
    Shylasree, Thumkur S.
    Kattepur, Abhay K.
    Gupta, Monisha
    Ghosh, Jaya
    Maheshwari, Amita
    Bajpai, Jyoti
    Hawaldar, Rohini
    Gulia, Seema
    Deodhar, Kedar
    Popat, Palak
    Gupta, Sudeep
    Kerkar, Rajendra A.
    CANCER REPORTS, 2020, 3 (02)
  • [46] Should neoadjuvant chemotherapy be preferred to an alternative treatment for advanced ovarian cancer: Comparison of neoadjuvant chemotherapy followed by interval debulking surgery and primary debulking surgery in patients with advanced ovarian cancer
    Liu, J.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 176 - 176
  • [47] Comparative analysis of neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer
    Sirop, S. J.
    Saha, S.
    Iddings, D.
    Ghanem, M.
    Dutt, N.
    Metz, J.
    Wilson, D.
    Weise, D.
    Arora, M. L.
    Singh, T.
    Eilender, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] Case report: Minimally invasive primary debulking surgery for advanced stage epithelial ovarian cancer
    Wolf, Jennifer
    Goncalves, Nicole
    Alagkiozidis, Ioannis
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [49] COMPARATIVE RETROSPECTIVE EVALUATION OF INTERVAL DEBULKING SURGERY VS PRIMARY SURGERY IN ADVANCED STAGE III OVARIAN CANCER
    Paillocher, N.
    Dessources, N. Hardy
    Oger, A. S.
    Augereau, P.
    Descamps, P. H.
    Catala, L.
    Raro, P.
    Wernert, R.
    Baton, O.
    Classe, J. M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1462 - 1462
  • [50] OPTIMAL RESIDUAL DISEASE AT PRIMARY DEBULKING SURGERY VERSUS COMPLETE TUMOR RESECTION AT INTERVAL DEBULKING SURGERY IN ADVANCED EPITHELIAL OVARIAN CANCER: A CASE-CONTROL SURVIVAL ANALYSIS
    Ghirardi, V.
    Bizzarri, N.
    Vargiu, V.
    D'Indinosante, M.
    Loverro, M.
    Pasciuto, T.
    Scambia, G.
    Fagotti, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A466 - A466